Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Loza

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
RMD Open|March 4, 2026
Nipocalimab and certolizumab combination therapy in participants with active rheumatoid arthritis despite prior treatment with advanced therapies: results from the phase 2a DAISY-RA studyPeter C Taylor, Georg Schett, Tom W J Huizinga, et al.
The Journal of Allergy and Clinical Immunology|January 17, 2017
Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patientsPhilip E Silkoff, Michel Laviolette, Dave Singh, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 3, 2020
Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus ErythematosusMatteo Cesaroni, Loqmane Seridi, Matthew J Loza, et al.
RMD Open|June 28, 2024
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA studyPeter C Taylor, Georg Schett, Tom Wj Huizinga, et al.
The Journal of Allergy and Clinical Immunology|May 22, 2017
Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthmaChristos Rossios, Stelios Pavlidis, Uruj Hoda, et al.
Human Vaccines & Immunotherapeutics|May 5, 2026
Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trialsFaye Yu, Eugene Myshkin, Brandon Nguyen, et al.
The European Respiratory Journal|November 2, 2016
Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED studySusan J Wilson, Jonathan A Ward, Ana R Sousa, et al.
The European Respiratory Journal|September 29, 2017
Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthmaPieter-Paul Hekking, Matthew J Loza, Stelios Pavlidis, et al.
The Journal of Allergy and Clinical Immunology|October 25, 2016
U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omicsDiane Lefaudeux, Bertrand De Meulder, Matthew J Loza, et al.
Plos One|September 22, 2018
Enhanced oxidative stress in smoking and ex-smoking severe asthma in the U-BIOPRED cohortRosalia Emma, Aruna T Bansal, Johan Kolmert, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
RMD Open|March 4, 2026
Nipocalimab and certolizumab combination therapy in participants with active rheumatoid arthritis despite prior treatment with advanced therapies: results from the phase 2a DAISY-RA studyPeter C Taylor, Georg Schett, Tom W J Huizinga, et al.
The Journal of Allergy and Clinical Immunology|January 17, 2017
Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patientsPhilip E Silkoff, Michel Laviolette, Dave Singh, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 3, 2020
Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus ErythematosusMatteo Cesaroni, Loqmane Seridi, Matthew J Loza, et al.
RMD Open|June 28, 2024
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA studyPeter C Taylor, Georg Schett, Tom Wj Huizinga, et al.
The Journal of Allergy and Clinical Immunology|May 22, 2017
Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthmaChristos Rossios, Stelios Pavlidis, Uruj Hoda, et al.
Human Vaccines & Immunotherapeutics|May 5, 2026
Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trialsFaye Yu, Eugene Myshkin, Brandon Nguyen, et al.
The European Respiratory Journal|November 2, 2016
Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED studySusan J Wilson, Jonathan A Ward, Ana R Sousa, et al.
The European Respiratory Journal|September 29, 2017
Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthmaPieter-Paul Hekking, Matthew J Loza, Stelios Pavlidis, et al.
The Journal of Allergy and Clinical Immunology|October 25, 2016
U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omicsDiane Lefaudeux, Bertrand De Meulder, Matthew J Loza, et al.
Plos One|September 22, 2018
Enhanced oxidative stress in smoking and ex-smoking severe asthma in the U-BIOPRED cohortRosalia Emma, Aruna T Bansal, Johan Kolmert, et al.
Pageof 6